At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 19, 2026 at 19:45 ET
Sutro Biopharma presented promising preclinical data for its next-generation antibody-drug conjugates (ADCs), including STRO-004, STRO-006, and STRO-227, demonstrating robust antitumor activity and favorable safety profiles. The data reinforce confidence in Sutro’s platform and support upcoming IND filings and clinical readouts in 2026. Partner Astellas also highlighted positive preclinical results for its TROP2-targeted iADC, ASP2998.
- STRO-004 showed strong antitumor activity across TF-expressing solid tumor PDX models at a 5 mg/kg dose, with improved efficacy vs. benchmark ADCs and a high HNSTD of 50 mg/kg, indicating a wide therapeutic window.
- STRO-006 demonstrated dose-dependent antitumor activity in NSCLC and head and neck cancers, with IND submission planned for 2026.
- STRO-227, a dual-payload ADC targeting PTK7, showed superior efficacy over single-payload ADCs in breast, ovarian, and NSCLC models; IND filing expected late 2026.
- Astellas’ TROP2-targeted iADC ASP2998, developed using Sutro’s platform, entered clinical dosing earlier in 2026 and showed potent efficacy and immune activation in preclinical models.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access